Sonoran Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sonoran Biosciences is a Scottsdale-based biotech founded in 2018, targeting two major unmet needs in surgical care: postoperative pain and surgical site infection (SSI). The company's core technology is the SB Gel, a biomaterial platform for localized, sustained drug release. Its lead candidates are SBG004, a sustained-release local anesthetic for pain, and SBG003, a sustained-release antimicrobial for SSI prevention, with both programs in development and supported by NIH SBIR funding.

Postoperative PainSurgical Site Infection

Technology Platform

SB Gel, a proprietary biomaterial for localized, sustained (multi-day) drug release directly to surgical sites.

Opportunities

Large addressable markets with ~14M painful surgeries and ~5M infection-prone surgeries annually in the U.S.

The shift toward opioid-sparing analgesia and the high cost of SSIs create strong demand for effective localized therapies.

QIDP designation for SBG003 offers a faster regulatory path and extended market exclusivity.

Risk Factors

High clinical development risk typical of biotech; both lead candidates must prove safety and efficacy in trials.

As a private, pre-revenue company, it faces significant funding risk to advance programs.

Faces competition from other companies developing long-acting local therapies.

Competitive Landscape

Competes in the sustained-release local drug delivery space for surgical applications. Potential competitors include companies with approved long-acting local anesthetics (e.g., Exparel from Pacira) and those developing local antimicrobial products. Sonoran's platform approach targeting both pain and infection could differentiate it from single-indication players.

More companies in Drug Delivery & Formulation →More companies in United States →